 Eiger BioPharmaceuticals, Inc. Nasdaq: EIGR, focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it has completed submission to the U.S. Food and Drug Administration FDA of a New Drug Application NDA for lonafarnib for the treatment of Progeria and Progeroid Laminopathies. The FDA previously granted Breakthrough Therapy Designation and Rare Pediatric Disease Designation to lonafarnib, which enables eligibility for Priority Review, if relevant criteria are met. Eiger expects to hear from FDA regarding submission acceptance and Priority Review within 60 days. 